SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-003817
Filing Date
2022-02-03
Accepted
2022-02-03 16:06:32
Documents
13
Period of Report
2022-02-02
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ubx-8k_20220202.htm   iXBRL 8-K 35510
2 EX-99.1 ubx-ex991_6.htm EX-99.1 18535
  Complete submission text file 0001564590-22-003817.txt   188743

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ubx-20220202.xsd EX-101.SCH 5714
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ubx-20220202_lab.xml EX-101.LAB 19419
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ubx-20220202_pre.xml EX-101.PRE 11595
7 EXTRACTED XBRL INSTANCE DOCUMENT ubx-8k_20220202_htm.xml XML 3559
Mailing Address 3280 BAYSHORE BOULEVARD BRISBANE CA 94005
Business Address 3280 BAYSHORE BOULEVARD BRISBANE CA 94005 (415) 328-5504
Unity Biotechnology, Inc. (Filer) CIK: 0001463361 (see all company filings)

IRS No.: 264726035 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38470 | Film No.: 22588291
SIC: 2834 Pharmaceutical Preparations